|
1
|
D'Amico AV, Chen MH, Renshaw A, Loffredo M
and Kantoff PW: Long-term follow-up of a randomized trial of
radiation with or without androgen deprivation therapy for
localized prostate cancer. JAMA. 314:1291–1293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fedorov A, Fluckiger J, Ayers GD, Li X,
Gupta SN, Tempany C, Mulkern R, Yankeelov TE and Fennessy FM: A
comparison of two methods for estimating DCE-MRI parameters via
individual and cohort based AIFs in prostate cancer: A step towards
practical implementation. Magn Reson Imaging. 32:321–329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu EY, Massard C, Gross ME, Carducci MA,
Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC,
et al: Once-daily dasatinib: Expansion of phase II study evaluating
safety and efficacy of dasatinib in patients with metastatic
castration-resistant prostate cancer. Urology. 77:1166–1171. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Houédé N, Pulido M, Mourey L, Joly F,
Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin
MC, et al: A phase II trial evaluating the efficacy and safety of
efavirenz in metastatic castration-resistant prostate cancer.
Oncologist. 19:1227–1228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas R, Williams M, Sharma H, Chaudry A
and Bellamy P: A double-blind, placebo-controlled randomised trial
evaluating the effect of a polyphenol-rich whole food supplement on
PSA progression in men with prostate cancer-the U.K. NCRN Pomi-T
study. Prostate Cancer Prostatic Dis. 17:180–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Obakan P, Arisan ED, Coker-Gurkan A and
Palavan-Unsal N: Epibrassinolide-induced apoptosis regardless of
p53 expression via activating polyamine catabolic machinery, a
common target for androgen sensitive and insensitive prostate
cancer cells. Prostate. 74:1622–1633. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reshma RS, Sreelatha KH, Somasundaram V,
Satheesh Kumar S, Nadhan R, Nair RS and Srinivas P: Plumbagin, a
naphthaquinone derivative induces apoptosis in BRCA 1/2 defective
castrate resistant prostate cancer cells as well as prostate cancer
stem-like cells. Pharmacol Res. 105:134–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwegyir-Afful AK, Ramalingam S,
Purushottamachar P, Ramamurthy VP and Njar VC: Galeterone and
VNPT55 induce proteasomal degradation of AR/AR-V7, induce
significant apoptosis via cytochrome c release and suppress growth
of castration resistant prostate cancer xenografts in vivo.
Oncotarget. 6:27440–27460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu B, Fukada K, Zhu H and Kyprianou N:
Prohibitin and cofilin are intracellular effectors of transforming
growth factor beta signaling in human prostate cancer cells. Cancer
Res. 66:8640–8647. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu LI, Fu NI, Luo XU, Li XY and Li XP:
Overexpression of cofilin 1 in prostate cancer and the
corresponding clinical implications. Oncol Lett. 9:2757–2761. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sundram V, Chauhan SC, Ebeling M and Jaggi
M: Curcumin attenuates β-catenin signaling in prostate cancer cells
through activation of protein kinase D1. PLoS One. 7:e353682012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hammes SR, Miedlich SU and Sen A: Paxillin
and steroid signaling: From frog to human. Methods Mol Biol.
1204:95–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bokobza SM, Ye L, Kynaston HG and Jiang
WG: Growth and differentiation factor-9 promotes adhesive and
motile capacity of prostate cancer cells by up-regulating FAK and
Paxillin via Smad dependent pathway. Oncol Rep. 24:1653–1659. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Janyou A, Changtam C, Suksamrarn A,
Tocharus C and Tocharus J: Suppression effects of
O-demethyldemethoxycurcumin on thapsigargin triggered on
endoplasmic reticulum stress in SK-N-SH cells. Neurotoxicology.
50:92–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Drexler HC: Synergistic apoptosis
induction in leukemic cells by the phosphatase inhibitor salubrinal
and proteasome inhibitors. PLoS One. 4:e41612009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Muramatsu Y, Maemoto T, Iwashita A and
Matsuoka N: Novel neuroprotective compound SCH-20148 rescues
thymocytes and SH-SY5Y cells from thapsigargin-induced
mitochondrial membrane potential reduction and cell death. Eur J
Pharmacol. 563:40–48. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky
LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla
T, et al: Global, multicenter, randomized, phase II trial of
gemcitabine and gemcitabine plus AGS-1C4D4 in patients with
previously untreated, metastatic pancreatic cancer. Ann Oncol.
24:1792–1801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsumoto K, Hagiwara M, Tanaka N,
Hayakawa N, Ishida M, Ninomiya A, Nakajima Y and Nakamura S:
Survival following primary androgen deprivation therapy for
localized intermediate- or high-risk prostate cancer: Comparison
with the life expectancy of the age-matched normal population. Med
Oncol. 31:9792014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cella D, Ivanescu C, Holmstrom S, Bui CN,
Spalding J and Fizazi K: Impact of enzalutamide on quality of life
in men with metastatic castration-resistant prostate cancer after
chemotherapy: Additional analyses from the AFFIRM randomized
clinical trial. Ann Oncol. 26:179–185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kato M, Banuelos CA, Imamura Y, Leung JK,
Caley DP, Wang J, Mawji NR and Sadar MD: Cotargeting androgen
receptor splice variants and mTOR signaling pathway for the
treatment of castration-resistant prostate cancer. Clin Cancer Res.
22:2744–2754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang F and Wang L, Zhang S, Fang Q, Hao F,
Sun Y, Zhao L, Chen S, Liao H and Wang L: CD147 modulates autophagy
through the PI3K/Akt/mTOR pathway in human prostate cancer PC-3
cells. Oncol Lett. 9:1439–1443. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chiu LY, Hu ME, Yang TY, Hsin IL, Ko JL,
Tsai KJ and Sheu GT: Immunomodulatory protein from ganoderma
microsporum induces pro-death autophagy through Akt-mTOR-p70S6K
pathway inhibition in multidrug resistant lung cancer cells. PLoS
One. 10:e01257742015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Asahara S, Shibutani Y, Teruyama K, Inoue
HY, Kawada Y, Etoh H, Matsuda T, Kimura-Koyanagi M, Hashimoto N,
Sakahara M, et al: Ras-related C3 botulinum toxin substrate 1
(RAC1) regulates glucose-stimulated insulin secretion via
modulation of F-actin. Diabetologia. 56:1088–1097. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu Y, Yang O, Fazli L, Rennie PS, Gleave
ME and Dong X: Progesterone receptor expression during prostate
cancer progression suggests a role of this receptor in stromal cell
differentiation. Prostate. 75:1043–1050. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo Y, Cui X, Zhao J, Han Y, Li M, Lin Y,
Jiang Y and Lan L: Cells susceptible to epithelial-mesenchymal
transition are enriched in stem-like side population cells from
prostate cancer. Oncol Rep. 31:874–884. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yip KH, Zheng MH, Steer JH, Giardina TM,
Han R, Lo SZ, Bakker AJ, Cassady AI, Joyce DA and Xu J:
Thapsigargin modulates osteoclastogenesis through the regulation of
RANKL-induced signaling pathways and reactive oxygen species
production. J Bone Miner Res. 20:1462–1471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang F, Liu DZ, Xu H, Li Y, Wang W, Liu BL
and Zhang LY: Thapsigargin induces apoptosis by impairing
cytoskeleton dynamics in human lung adenocarcinoma cells.
ScientificWorldJournal. 2014:6190502014.PubMed/NCBI
|
